Thomas Cahill - Oct 19, 2022 Form 3 Insider Report for Prime Medicine, Inc. (PRME)

Role
Director
Signature
/s/ Carman Alenson attorney-in-fact
Stock symbol
PRME
Transactions as of
Oct 19, 2022
Transactions value $
$0
Form type
3
Date filed
10/19/2022, 08:03 PM
Next filing
Oct 26, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRME Series A Convertible Preferred Stock Oct 19, 2022 Common Stock 3.22M By Newpath Partners, L.P. F1, F2
holding PRME Series B Convertible Preferred Stock Oct 19, 2022 Common Stock 1.69M By Newpath Partners, L.P. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") are convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date.
F2 Represents shares held directly by Newpath Partners, L.P. ("Newpath LP"). Newpath Partners GP, L.P. ("Newpath GP LP") is the general partner of Newpath LP. Newpath Partners GP, LLC ("Newpath GP LLC") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose

Remarks:

Exhibit 24 - Power of Attorney